Preferential vulnerability of mesencephalic dopamine neurons to glutamate transporter dysfunction

Journal of Neurochemistry

Volumn 105, Issue 2, 2008, Pages 484-496

  Nafia, Imane ^a   Re, Diane B ^a,b   Masmejean, Frédérique ^a   Melon, Christophe ^a   Kachidian, Philippe ^a   Kerkerian Le Goff, Lydia ^a   Nieoullon, André ^a   Had Aissouni, Laurence ^a  

^a AIX MARSEILLE UNIVERSITÉ   (France)

^b Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Excitatory amino acid transporters; GSH; Mesencephalic dopamine neurons; NMDA receptor mediated excitotoxicity; Oxidative stress; Parkinson's disease

Indexed keywords

2,4 PYRROLIDINEDICARBOXYLIC ACID; ALPHA SYNUCLEIN; EXCITATORY AMINO ACID TRANSPORTER 1; GLUTAMATE TRANSPORTER; GLUTATHIONE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; EMBRYO; EXCITOTOXICITY; FEMALE; MESENCEPHALON; NERVE CELL NECROSIS; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN EXPRESSION; RAT;

ALPHA-SYNUCLEIN; ANALYSIS OF VARIANCE; ANIMALS; ASPARTIC ACID; CELLS, CULTURED; DICARBOXYLIC ACIDS; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; EMBRYO, MAMMALIAN; EXCITATORY AMINO ACID ANTAGONISTS; EXCITATORY AMINO ACID TRANSPORTER 1; FEMALE; GLIAL FIBRILLARY ACIDIC PROTEIN; GLUTAMIC ACID; MESENCEPHALON; NEURONS; NEUROTRANSMITTER UPTAKE INHIBITORS; PHOSPHOPYRUVATE HYDRATASE; PREGNANCY; PYRROLIDINES; RATS; RATS, WISTAR; REACTIVE OXYGEN SPECIES; TYROSINE 3-MONOOXYGENASE;

RATTUS;

EID: 41749084163     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2007.05146.x     Document Type: Article

References (72)

1. Antunes F., Nunes C., Laranjinha J. Cadenas E. (2005) Redox interactions of nitric oxide with dopamine and its derivatives. Toxicology 208, 207 212.
2. Aoyama K., Suh S. W., Hamby A. M., Liu J., Chan W. Y., Chen Y. Swanson R. A. (2006) Neuronal glutathione deficiency and age-dependent neurodegeneration in the EAAC1 deficient mouse. Nat. Neurosci. 9, 119 126.
3. Arriza J. L., Fairman W. A., Wadiche J. I., Murdoch G. H., Kavanaugh M. P. Amara S. G. (1994) Functional comparisons of three glutamate transporter subtypes cloned from human motor cortex. J. Neurosci. 14, 5559 5569.
4. Beart P. M. O'Shea R. D. (2007) Transporters for l-glutamate: an update on their molecular pharmacology and pathological involvement. Br. J. Pharmacol. 150, 5 17.
5. Berman S. B. Hastings T. G. (1997) Inhibition of glutamate transport in synaptosomes by dopamine oxidation and reactive oxygen species. J. Neurochem. 69, 1185 1195.
6. de Bernardo S., Canals S., Casarejos M. J., Solano R. M., Menendez J. Mena M. A. (2004) Role of extracellular signal-regulated protein kinase in neuronal cell death induced by glutathione depletion in neuron/glia mesencephalic cultures. J. Neurochem. 91, 667 682.
7. Bharath S., Hsu M., Kaur D., Rajagopalan S. Andersen J. K. (2002) Glutathione, iron and Parkinson's disease. Biochem. Pharmacol. 64, 1037 1048.
8. Blandini F., Greenamyre J. T. Nappi G. (1996) The role of glutamate in the pathophysiology of Parkinson's disease. Funct. Neurol. 11, 3 15.
9. Bloc A., Samuel D., Forni C., Dusticier N. Kerkerian-Le Goff L. (1995) Effects of ionotropic excitatory amino acid receptor antagonists on glutamate transport and transport-mediated changes in extracellular excitatory amino acids in the rat striatum. J. Neurochem. 64, 1598 1604.
10. Canals S., Casarejos M. J., de Bernardo S., Rodriguez-Martin E. Mena M. A. (2001) Glutathione depletion switches nitric oxide neurotrophic effects to cell death in midbrain cultures: implications for Parkinson's disease. J. Neurochem. 79, 1183 1195.
11. Casarejos M. J., Solano R. M., Menendez J., Rodriguez-Navarro J. A., Correa C., Garcia de Yebenes J. Mena M. A. (2005) Differential effects of l-DOPA on monoamine metabolism, cell survival and glutathione production in midbrain neuronal-enriched cultures from parkin knockout and wild-type mice. J. Neurochem. 94, 1005 1014.
12. Chen Y. Swanson R. A. (2003) The glutamate transporters EAAT2 and EAAT3 mediate cysteine uptake in cortical neuron cultures. J. Neurochem. 84, 1332 1339.
13. + toxicity in cultured dopaminergic cells. J. Neurosci. Res. 73, 811 817.
14. Coyle J. T. Puttfarcken P. (1993) Oxidative stress, glutamate, and neurodegenerative disorders. Science 262, 689 695.
15. Damier P., Hirsch E. C., Agid Y. Graybiel A. M. (1999) The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain 122 (Pt. 8 1437 1448.
16. Danbolt N. C. (2001) Glutamate uptake. Prog. Neurobiol. 65, 1 105.
17. Dauer W. Przedborski S. (2003) Parkinson's disease: mechanisms and models. Neuron 39, 889 909.
18. Dringen R. (2000) Metabolism and functions of glutathione in brain. Prog. Neurobiol. 62, 649 671.
19. Fillenz M. (1995) Physiological release of excitatory amino acids. Behav. Brain Res. 71, 51 67.
20. Fonnum F. (1984) Glutamate: a neurotransmitter in mammalian brain. J. Neurochem. 42, 1 11.
21. Fornai F., Schluter O. M., Lenzi P. et al. (2005) Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and alpha-synuclein. Proc. Natl Acad. Sci. USA 102, 3413 3418.
22. Gerlach M., Double K. L., Ben-Shachar D., Zecca L., Youdim M. B. Riederer P. (2003) Neuromelanin and its interaction with iron as a potential risk factor for dopaminergic neurodegeneration underlying Parkinson's disease. Neurotox. Res. 5, 35 44.
23. Graham D. G. (1978) Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol. Pharmacol. 14, 633 643.
24. Gramsbergen J. B., Sandberg M., Moller Dall A., Kornblit B. Zimmer J. (2002) Glutathione depletion in nigrostriatal slice cultures: GABA loss, dopamine resistance and protection by the tetrahydrobiopterin precursor sepiapterin. Brain Res. 935, 47 58.
25. de Groot J. (1959) The rat forebrain in stereotaxic coordinates. Verh. Konink. Nederland Akad. Wetenschap, Natuurkunde. 52, 1 40.
26. Guillet B., Lortet S., Masmejean F., Samuel D., Nieoullon A. Pisano P. (2002) Developmental expression and activity of high affinity glutamate transporters in rat cortical primary cultures. Neurochem. Int. 40, 661 671.
27. Guiramand J., Martin A., de Jesus Ferreira M. C., Cohen-Solal C., Vignes M. Recasens M. (2005) Gliotoxicity in hippocampal cultures is induced by transportable, but not by nontransportable, glutamate uptake inhibitors. J. Neurosci. Res. 81, 199 207.
28. Hallett P. J. Standaert D. G. (2004) Rationale for and use of NMDA receptor antagonists in Parkinson's disease. Pharmacol. Ther. 102, 155 174.
29. Hayes D., Wiessner M., Rauen T. McBean G. J. (2005) Transport of l-[14C]cystine and l-[14C]cysteine by subtypes of high affinity glutamate transporters over-expressed in HEK cells. Neurochem. Int. 46, 585 594.
30. Hazell A. S., Itzhak Y., Liu H. Norenberg M. D. (1997) 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) decreases glutamate uptake in cultured astrocytes. J. Neurochem. 68, 2216 2219.
31. Hertz L. (2006) Glutamate, a neurotransmitter - and so much more. A synopsis of Wierzba III. Neurochem. Int. 48, 416 425.
32. Hirsch E. C., Hunot S. Hartmann A. (2005) Neuroinflammatory processes in Parkinson's disease. Parkinsonism Relat. Disord. 11 (Suppl. 1 S9 S15.
33. Hoglinger G. U., Carrard G., Michel P. P., Medja F., Lombes A., Ruberg M., Friguet B. Hirsch E. C. (2003) Dysfunction of mitochondrial complex I and the proteasome: interactions between two biochemical deficits in a cellular model of Parkinson's disease. J. Neurochem. 86, 1297 1307.
34. Jameson G. N., Zhang J., Jameson R. F. Linert W. (2004) Kinetic evidence that cysteine reacts with dopaminoquinone via reversible adduct formation to yield 5-cysteinyl-dopamine: an important precursor of neuromelanin. Org. Biomol. Chem. 2, 777 782.
35. Jenner P. (2003) Oxidative stress in Parkinson's disease. Ann. Neurol. 53 (Suppl. 3 S26 S36.
36. Jha N., Kumar M. J., Boonplueang R. Andersen J. K. (2002) Glutathione decreases in dopaminergic PC12 cells interfere with the ubiquitin protein degradation pathway: relevance for Parkinson's disease? J. Neurochem. 80, 555 561.
37. Jones S. Gibb A. J. (2005) Functional NR2B- and NR2D-containing NMDA receptor channels in rat substantia nigra dopaminergic neurones. J. Physiol. 569, 209 221.
38. Kanai Y. Hediger M. A. (1992) Primary structure and functional characterization of a high-affinity glutamate transporter. Nature 360, 467 471.
39. Koch H. P., Kavanaugh M. P., Esslinger C. S., Zerangue N., Humphrey J. M., Amara S. G., Chamberlin A. R. Bridges R. J. (1999) Differentiation of substrate and nonsubstrate inhibitors of the high-affinity, sodium-dependent glutamate transporters. Mol. Pharmacol. 56, 1095 1104.
40. Liévens J.-C., Dutertre M., Forni C., Salin P. Kerkerian-Le Goff L. (1997) Continuous administration of the glutamate uptake inhibitor l-trans-pyrrolidine-2,4-dicarboxylate produces striatal lesion. Brain Res. Mol. Brain Res. 50, 181 189.
41. Lowry O. H., Rosebrough N. J., Farr A. L. Randall R. J. (1951) Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193, 265 275.
42. Massieu L., Morales-Villagran A. Tapia R. (1995) Accumulation of extracellular glutamate by inhibition of its uptake is not sufficient for inducing neuronal damage: an in vivo microdialysis study. J. Neurochem. 64, 2262 2272.
43. Massieu L., Del Rio P. Montiel T. (2001) Neurotoxicity of glutamate uptake inhibition in vivo: correlation with succinate dehydrogenase activity and prevention by energy substrates. Neuroscience 106, 669 677.
44. Montiel T., Camacho A., Estrada-Sanchez A. M. Massieu L. (2005) Differential effects of the substrate inhibitor l-trans-pyrrolidine-2,4- dicarboxylate (PDC) and the non-substrate inhibitor dl-threo-beta- benzyloxyaspartate (dl-TBOA) of glutamate transporters on neuronal damage and extracellular amino acid levels in rat brain in vivo. Neuroscience 133, 667 678.
45. Moore D. J., West A. B., Dawson V. L. Dawson T. M. (2005) Molecular pathophysiology of Parkinson's disease. Annu. Rev. Neurosci. 28, 57 87.
46. Mytilineou C., Han S. K. Cohen G. (1993) Toxic and protective effects of l-dopa on mesencephalic cell cultures. J. Neurochem. 61, 1470 1478.
47. Mytilineou C., Kokotos Leonardi E. T., Kramer B. C., Jamindar T. Olanow C. W. (1999) Glial cells mediate toxicity in glutathione-depleted mesencephalic cultures. J. Neurochem. 73, 112 119.
48. Nakamura K., Wang W. Kang U. J. (1997) The role of glutathione in dopaminergic neuronal survival. J. Neurochem. 69, 1850 1858.
49. Nakamura K., Won L., Heller A. Kang U. J. (2000) Preferential resistance of dopaminergic neurons to glutathione depletion in a reconstituted nigrostriatal system. Brain Res. 873, 203 211.
50. Plaitakis A. Shashidharan P. (2000) Glutamate transport and metabolism in dopaminergic neurons of substantia nigra: implications for the pathogenesis of Parkinson's disease. J. Neurol. 247 (Suppl. 2 II25 II35.
51. Rabinovic A. D. Hastings T. G. (1998) Role of endogenous glutathione in the oxidation of dopamine. J. Neurochem. 71, 2071 2078.
52. Re D. B., Boucraut J., Samuel D., Birman S., Kerkerian-Le Goff L. Had-Aissouni L. (2003) Glutamate transport alteration triggers differentiation-state selective oxidative death of cultured astrocytes: a mechanism different from excitotoxicity depending on intracellular GSH contents. J. Neurochem. 85, 1159 1170.
53. Re D. B., Nafia I., Melon C., Shimamoto K., Kerkerian-Le Goff L. Had-Aissouni L. (2006) Glutamate leakage from a compartmentalized intracellular metabolic pool and activation of the lipoxygenase pathway mediate oxidative astrocyte death by reversed glutamate transport. Glia 54, 47 57.
54. Rodriguez M. C., Obeso J. A. Olanov C. W. (1998) Subthalamic nucleus-mediated excitotoxicity in Parkinson's disease: a target for neuroprotection. Ann. Neurol. 44, S175 S188.
55. +) enhances glutamate-induced cytotoxicity against dopaminergic neurons in cultured rat mesencephalon. J. Neurosci. Res. 43, 55 62.
56. Shashidharan P., Huntley G. W., Meyer T., Morrison J. H. Plaitakis A. (1994) Neuron-specific human glutamate transporter: molecular cloning, characterization and expression in human brain. Brain Res. 662, 245 250.
57. Shashidharan P., Huntley G. W., Murray J. M., Buku A., Moran T., Walsh M. J., Morrison J. H. Plaitakis A. (1997) Immunohistochemical localization of the neuron-specific glutamate transporter EAAC1 (EAAT3) in rat brain and spinal cord revealed by a novel monoclonal antibody. Brain Res. 773, 139 148.
58. Shimamoto K., Lebrun B., Yasuda-Kamatani Y., Sakaitani M., Shigeri Y., Yumoto N. Nakajima T. (1998) dl-threo-beta-benzyloxyaspartate, a potent blocker of excitatory amino acid transporters. Mol. Pharmacol. 53, 195 201.
59. Sian J., Dexter D. T., Lees A. J., Daniel S., Agid Y., Javoy-Agid F., Jenner P. Marsden C. D. (1994a) Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann. Neurol. 36, 348 355.
60. Sian J., Dexter D. T., Lees A. J., Daniel S., Jenner P. Marsden C. D. (1994b) Glutathione-related enzymes in brain in Parkinson's disease. Ann. Neurol. 36, 356 361.
61. Spillantini M. G., Schmidt M. L., Lee V. M., Trojanowski J. Q., Jakes R. Goedert M. (1997) Alpha-synuclein in Lewy bodies. Nature 388, 839 840.
62. Suchak S. K., Baloyianni N. V., Perkinton M. S., Williams R. J., Meldrum B. S. Rattray M. (2003) The 'glial' glutamate transporter, EAAT2 (GLT-1) accounts for high affinity glutamate uptake into adult rodent nerve endings. J. Neurochem. 84, 522 532.
63. Szatkowski M., Barbour B. Attwell D. (1990) Non-vesicular release of glutamate from glial cells by reversed electrogenic glutamate uptake. Nature 348, 443 446.
64. Toffa S., Kunikowska G. M., Zeng B. Y., Jenner P. Marsden C. D. (1997) Glutathione depletion in rat brain does not cause nigrostriatal pathway degeneration. J. Neural Transm. 104, 67 75.
65. + neurotoxicity by N-methyl-d-aspartate antagonists. Nature 349, 414 418.
66. Volterra A., Bezzi P., Rizzini B. L., Trotti D., Ullensvang K., Danbolt N. C. Racagni G. (1996) The competitive transport inhibitor l-trans-pyrrolidine- 2, 4-dicarboxylate triggers excitotoxicity in rat cortical neuron-astrocyte co-cultures via glutamate release rather than uptake inhibition. Eur. J. Neurosci. 8, 2019 2028.
67. Waagepetersen H. S., Shimamoto K. Schousboe A. (2001) Comparison of effects of dl-threo-beta-benzyloxyaspartate (dl-TBOA) and l-trans-pyrrolidine-2, 4-dicarboxylate (t-2,4-PDC) on uptake and release of D-aspartate in astrocytes and glutamatergic neurons. Neurochem. Res. 26, 661 666.
68. Wang G. J., Chung H. J., Schnuer J., Pratt K., Zable A. C., Kavanaugh M. P. Rosenberg P. A. (1998) High affinity glutamate transport in rat cortical neurons in culture. Mol. Pharmacol. 53, 88 96.
69. + toxicity in nigral dopaminergic neurones. Neuroreport 7, 921 923.
70. Yantiri F., Gasparyan A. Andersen J. K. (2001) Glutamyl cysteine synthetase catalytic and regulatory subunits localize to dopaminergic nigral neurons as well as to astrocytes. J. Neurosci. Res. 64, 203 206.
71. Yao H. H., Ding J. H., He H. R. Hu G. (2004) Inhibitory effects of 1-methyl-4-phenylpyridinium on glutamate uptake into cultured C6 glioma cells. Acta Pharmacol. Sin. 25, 855 860.
72. Zeevalk G. D., Bernard L. P., Sinha C., Ehrhart J. Nicklas W. J. (1998) Excitotoxicity and oxidative stress during inhibition of energy metabolism. Dev. Neurosci. 20, 444 453.